Patients experiencing suspected adverse effects should report them to their healthcare provider and to the FDA MedWatch program
Peptides 30 , 17531762 (2009)
"If they don't follow those rules, then they may no longer be eligible to get the medication
Watanabe T, Tamura Y, Kakehi S et al (2015) Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study
Your cost depends on which compound you are prescribed, whether it is oral or injectable, and how many months you prepay, so two customers can pay very different monthly totals for the same program
Sci Rep 12(1):6666 Liu C, Li C, Cai X, Zou Y, Mo J, Chen B, Cai Y, Han T, Huang W, Qian H, Zhang W (2021) Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent